This is a post-marketing drug safety monitoring study in a prospective manner, and data collection will be performed in a registration-follow-up manner. Safety information about patients who have received intravitreal injection of Conbercept Ophthalmic Injection in medical institutions involved in the study during research will be actively monitored without intervening in diagnosis and treatment. All patients enrolled will be followed up for one year.
Study Type
OBSERVATIONAL
Enrollment
4,000
New Adverse Reactions
To observe the type, incidence and severity of new adverse reactions in patients who have received intravitreal injection of Conbercept Ophthalmic Injection during the study;
Time frame: 1 year
Common Ocular Adverse Events
To observe the type, incidence and severity of common ocular adverse events in patients who have received intravitreal injection of Conbercept Ophthalmic Injection during the study, including: 1) bleeding at injection site; 2) increased intraocular pressure (IOP); 3) conjunctival congestion; 4) conjunctivitis; 5) decreased visual sensitivity; and 6) muscae volitantes.
Time frame: 1 year
Common Ocular Adverse Events
To evaluate the Common Ocular AEs' correlation with Conbercept Ophthalmic Injection therapy.
Time frame: 1 year
Other Ocular Adverse Events
To observe the type, incidence and severity of other ocular adverse events in patients who have received intravitreal injection of Conbercept Ophthalmic Injection during the study.
Time frame: 1 year
Other Ocular Adverse Events
To evaluate the Other Ocular AEs' correlation with Conbercept Ophthalmic Injection therapy.
Time frame: 1 year
Non-ocular Adverse Events
To observe the type, incidence and severity of non-ocular adverse events during the study
Time frame: 1 year
Non-ocular Adverse Events
To evaluate the Non-ocular AEs' correlation with Conbercept Ophthalmic Injection therapy.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Baoji People'S Hospital
Baoji, China
NOT_YET_RECRUITINGBeijing Aier-Intech Eye Hospital
Beijing, China
RECRUITINGBeijing Tongren Hospital, Cmu
Beijing, China
NOT_YET_RECRUITINGEye Hospital, China Academy of Chinese Medical Sciences
Beijing, China
NOT_YET_RECRUITINGPeking Union Medical College Hospital
Beijing, China
NOT_YET_RECRUITINGPeking University Third Hospital
Beijing, China
NOT_YET_RECRUITINGThe 306Th Hospital of Pla
Beijing, China
NOT_YET_RECRUITINGXuanwu Hospital Capital Medical University
Beijing, China
NOT_YET_RECRUITINGSichuan Provincial People's Hospital
Chengdu, China
NOT_YET_RECRUITINGThe Second Affiliated Hospital of Chongqing Medical University
Chongqing, China
NOT_YET_RECRUITING...and 39 more locations
Time frame: 1 year
Adverse Events of Special Interest(AESI)
To observe the incidence and severity of adverse events of special interest (AESI) during the study, including: 1) retinal detachment; 2) retinal tears; 3) retinal pigment epithelial detachment; 4) retinal pigment epithelium tears; 5) geographic atrophy; 6) endophthalmitis; 7) arterial thromboembolic events (ATEs); and 8) hypertension
Time frame: 1 year
Adverse Events of Special Interest(AESI)
To evaluate the AESI's correlation with Conbercept Ophthalmic Injection therapy.
Time frame: 1 year
SAE
To observe the type, incidence and severity of all severe adverse events during the study
Time frame: 1 year
SAE
To evaluate the SAEs' correlation with Conbercept Ophthalmic Injection therapy.
Time frame: 1 year
Adverse Events Related to Intravitreal Injection Practices
To observe the incidence and severity of possible adverse events related to intravitreal injection practices of Conbercept Ophthalmic Injection during the study.
Time frame: 1 year
Adverse Events of Special Population
To observe the incidence and severity of adverse events of special population during the study,including children and adolescents (aged under 18), and pregnant women.
Time frame: 1 year
Adverse Events of Special Population
To evaluate the AEs' correlation with Conbercept Ophthalmic Injection therapy.
Time frame: 1 year